指南与共识支持与姑息治疗

AGIHO循证指南更新:G-CSF预防成人肿瘤感染并发症

Evidence-based AGIHO guideline update on prophylaxis of infectious complications with granulocyte-stimulating factors (G-CSF) for the treatment of adult patients with cancer.
指南 / 共识 · Eur J Cancer · 2026-01-16

多数2014年关键推荐获确认,新增免疫治疗场景下G-CSF使用推荐。

要点

  • 系统检索2014–2024年文献并更新G-CSF预防感染并发症推荐。
  • 多数2014年关键推荐经专家共识确认。
  • 新增免疫治疗场景下G-CSF使用推荐。

核心结论

  • 综合文献检索与专家共识确认2014版多数关键推荐。
  • 新增免疫治疗场景下G-CSF使用推荐以支持临床决策。

研究设计与样本

  • 召开多次共识会议,基于ESCMID标准评估证据等级与推荐强度。

主要发现

  • 符合条件的(随机)研究结果被汇总至证据表。
  • 针对不同实体瘤、风险组、新G-CSF制剂及免疫治疗新兴策略制定推荐并与2014版比较。

临床怎么用

  • 为成人肿瘤患者G-CSF预防感染并发症提供循证推荐。
  • 新增免疫治疗场景推荐支持日常临床决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Febrile neutropenia, a common complication of systemic antineoplastic therapy, varies in risk depending on malignant disease, treatment, and patient factors. The risk increases with the depth and duration of neutropenia and can be reduced with prophylactic use of G-CSF. International guidelines are conflicting in several aspects and do not reflect all patient groups. We therefore updated the 2014 Infectious Diseases Working Party (AGIHO) guideline of the German Society of Hematology and Medical Oncology (DGHO) on evidence-based recommendations for the use of G-CSF in patients with cancer. MATERIALS AND METHODS: After a systematic literature search from January 2014 to December 2024 on PubMed and Medline several consensus meetings were held by an expert panel of the AGIHO to evaluate, discuss and consent on the level of evidence and strength of recommendation for the use of G-CSF in patients with cancer based on ESCMID criteria. RESULTS: Results from eligible (randomized) studies were grouped in evidence tables. Recommendations for different entities, risk groups, new G-CSF formulations and emerging strategies in immunotherapy were set up and put into comparison to 2014. DISCUSSION: Comprehensive literature search and expert panel consensus confirm most of the key recommendations of 2014. New recommendations on the use of G-CSF in immunotherapy settings provide insight and support for day-by-day clinical decision making in the care of patients with cancer.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Sandherr M, Schalk E, Heinz WJ, et al. Evidence-based AGIHO guideline update on prophylaxis of infectious complications with granulocyte-stimulating factors (G-CSF) for the treatment of adult patients with cancer. Eur J Cancer. 2026. PMID: 41570611. doi:10.1016/j.ejca.2026.116244

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。